سعر انتجريلين 0.75 مجم / مل محلول 100 مل 2022

Integrilin: eptifibatide 0.75 mg/ml solution for intravenous infusion, 100 ml vial (manufactured by Patheon Italia; marketed in Egypt via the MSD scientific office). Hospital use in acute coronary syndromes.

• For use with acetylsalicylic acid and unfractionated heparin for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain within 24 hours and with ECG changes and/or elevated cardiac enzymes.Population: AdultsEuropean Medicines Agency (EMA) - EPAR product information
• Acute coronary syndrome (unstable angina or NSTEMI), managed medically or with PCI, to decrease the rate of death or new myocardial infarction.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Percutaneous coronary intervention, including procedures involving intracoronary stenting, to decrease the rate of death, new myocardial infarction or need for urgent intervention.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Bleeding is very common (minor bleeding 13.1% vs 7.6% with placebo; major bleeding 10.8% vs 9.3% in PURSUIT). Common: cardiac arrest, ventricular fibrillation, ventricular tachycardia, congestive heart failure, atrioventricular block, atrial fibrillation, shock, hypotension, phlebitis. Uncommon: thrombocytopenia, cerebral ischaemia. Very rare: fatal bleeding, acute profound thrombocytopenia, anaphylactic reactions, rash.International label, same formulation · European Medicines Agency (EMA) - EPAR product information

• Evidence of gastrointestinal bleeding, gross genitourinary bleeding or other active abnormal bleeding within the previous 30 days; stroke within 30 days or any history of haemorrhagic stroke; known intracranial disease (neoplasm, arteriovenous malformation, aneurysm); major surgery or severe trauma within 6 weeks; history of haemorrhagic diathesis; thrombocytopenia (<100,000/mm3); prothrombin time >1.2 x control or INR >=2.0; severe hypertension (systolic >200 or diastolic >110 mm Hg on treatment); severe renal impairment (CrCl <30 ml/min) or dependency on dialysis; clinically significant hepatic impairment; concomitant or planned use of another parenteral GP IIb/IIIa inhibitor; hypersensitivity.International label, same formulation · European Medicines Agency (EMA) - EPAR product information
• History of bleeding diathesis or active abnormal bleeding within 30 days; severe hypertension not adequately controlled; major surgery within 6 weeks; history of stroke within 30 days or any haemorrhagic stroke; current or planned use of another parenteral GP IIb/IIIa inhibitor; dependency on renal dialysis; known hypersensitivity to any component.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Bleeding is the most common complication; most major bleeding occurs at the arterial access site for cardiac catheterisation. Minimise vascular and other trauma; if bleeding cannot be controlled with pressure, stop eptifibatide and heparin. Thrombocytopenia, including acute profound thrombocytopenia, can occur; discontinue eptifibatide and heparin if platelets fall below 100,000/mm3.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Antiplatelet agents, thrombolytics, heparin, aspirin, chronic NSAID use; other GP IIb/IIIa inhibitorsCo-administration increases the risk of bleeding; concomitant treatment with other GP IIb/IIIa inhibitors should be avoided.DailyMed (U.S. National Library of Medicine)
• Other parenteral glycoprotein IIb/IIIa inhibitorsConcomitant use is contraindicated.European Medicines Agency (EMA) - EPAR product information

• There are no adequate data on the use of eptifibatide in pregnant women; it should not be used during pregnancy unless clearly necessary.International label, same formulation · European Medicines Agency (EMA) - EPAR product information
• Available data are insufficient to establish a drug-associated risk of major birth defects or miscarriage; untreated myocardial infarction can be fatal to the pregnant woman and fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• It is not known whether eptifibatide is excreted in human milk; interruption of breastfeeding during treatment is recommended.International label, same formulation · European Medicines Agency (EMA) - EPAR product information

• Eptifibatide: Cyclic heptapeptide that reversibly inhibits platelet aggregation by preventing binding of fibrinogen, von Willebrand factor and other adhesive ligands to the glycoprotein IIb/IIIa receptor.